Expression of the retinoblastoma-related gene Rb2/p130 correlates with clinical outcome in endometrial cancer.

Abstract

In patients with endometrial carcinoma who did not receive radiotherapy or chemotherapy before surgery, the presence of decreased levels of pRb2/p130 in tumor cells is associated with a significantly increased risk of recurrence and death of disease, independent of tumor stage and ploidy status.

Tumor suppressor genes in normal and malignant hematopoiesis

“…The likelihood that these alterations of p130 and p107 are causally linked to lymphomagenesis is supported by the following: Both p130 and p107, like Rb, negatively regulate cell cycle progression (Claudio et al, 1994;Zhu et al, 1995). For p130, high expression levels in various solid tumor samples correlated with more di erentiated tumors and better prognosis of the patients (Baldi et al, 1996(Baldi et al, , 1997Susini et al, 1998Susini et al, , 2001Tanaka et al, 1999Tanaka et al, , 2001Massaro-Giordano et al, 1999;Zamparelli et al, 2001). Even though mice with targeted disruption of either p130 (LeCouter et al, 1998) or p107 (Lee et al, 1996 are not predisposed to cancer, chimeric mice de®cient for Rb and p107 (Rb 7/7 /p107 7/7 ) display a high frequency of retinoblastomas (Robanus- Maandag et al, 1998), as compared to chimeric Rb 7/7 mice (Maandag et al, 1994;Williams et al, 1994).…”

RB family members as predictive and prognostic factors in human cancer

“…We previously demonstrated by immunohistochemistry that reduced expression of pRb2/p130 is a strong independent predictor of poor outcome in endometrial cancer (Susini et al, 1998). Specifically, decreased levels of pRb2/p130 in endometrial cancer cells were significantly associated with a decreased probability of remaining disease free after treatment (P ¼ 0.003) and with decreased probability of survival (Po0.0001).…”

Ten‐year results of a prospective study on the prognostic role of ploidy in endometrial carcinoma

“…This series includes a cohort presented in a previous report on the prognostic value of Rb2/p130 gene expression. 28 Patient ages ranged from 41 to 93 (median, 64 years). Histologic slides were reviewed to assess histotype, grade of differentiation, and depth of myometrial invasion.…”

“…Hence, to improve the outcome of patients with endometrial cancer a new, more accurate prognostic assessment is mandatory to identify patients with high-risk disease. In recent years research focused on biological aspects of the tumor, such as DNA content, [8][9][10][11][12][13][14][15][16][17][18][19][20][21] protooncogenes, [22][23][24] and tumor-suppressor genes expression [25][26][27][28][29][30][31][32][33] that have been investigated as possible predictors of clinical outcome in endometrial cancer. The advantage of these parameters is that they are considered to provide objective and reproducible information.…”